Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
plerixafor GZ316455 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| granulocyte colony-stimulating factor alone | ACTIVE_COMPARATOR | G-CSF administered up to 8 days |
| granulocyte colony-stimulating factor plus plerixafor | EXPERIMENTAL | G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7) |
| Granulocyte colony-stimulating factor (G-CSF) alone | ACTIVE_COMPARATOR | G-CSF administered up to 8 days |
| G-CSF plus plerixafor | EXPERIMENTAL | G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7) |
| Name | Type | Description |
|---|---|---|
| plerixafor GZ316455 | DRUG | Pharmaceutical form:vial Route of administration: subcutaneous injection |
| Filgrastim | DRUG | Pharmaceutical form:vial Route of administration: subcutaneous injection |
Inclusion criteria: * Age 20 to 75. * Japanese participants with histological or pathological diagnosis of NHL. * First or second complete response (CR) or partial response (PR). Exclusion criteria: * Leukemia participants. * Myelodysplastic syndrome (MDS) participants. * Less than 2 weeks since ...
Top 20 of 66 competitors
Plerixafor GZ316455 is an investigational small molecule being studied for use in lymphoma and multiple myeloma. It is being developed to mobilize and collect peripheral hematopoietic stem cells in patients with these conditions, typically in combination with granulocyte colony-stimulating factor (G-CSF).
Plerixafor GZ316455 is being developed by Sanofi, a company traded under the ticker SNY. The drug is currently in Phase 2 clinical development for oncology indications including lymphoma and multiple myeloma.
Plerixafor GZ316455 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for this drug have been completed, with no active trials currently ongoing.
Plerixafor GZ316455 has been studied in two completed Phase 2 clinical trials in Japan. NCT02221479 enrolled 14 participants with multiple myeloma, and NCT02221492 enrolled 32 participants with non-Hodgkin lymphoma. Both trials evaluated plerixafor plus G-CSF for stem cell mobilization and collection.
Plerixafor GZ316455 is a form of plerixafor, a small molecule being developed by Sanofi. It is being studied for stem cell mobilization in patients with lymphoma and multiple myeloma, and has completed Phase 2 trials in Japan.